Atrion Corp (ATRI): Jeffery Strickland , CFO of Atrion Corp sold 1,100 shares on Apr 25, 2016. The Insider selling transaction was reported by the company on Apr 26, 2016 to the Securities and Exchange Commission. The shares were sold at $399.73 per share for a total value of $439,701.47 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 24, 2016, Jeffery Strickland (CFO) sold 50 shares at $380.23 per share price.On Aug 27, 2015, Ronald Nicholas Spaulding (director) sold 500 shares at $375.90 per share price.
Atrion Corporation: On Friday, Apr 22, 2016 heightened volatility was witnessed in Atrion Corporation which led to swings in the share price. The shares opened for trading at $402.99 and hit $403.81 on the upside , eventually ending the session at $402.51, with a gain of 0.62% or 2.4899 points. The heightened volatility saw the trading volume jump to 2,221 shares. The 52-week high of the share price is $428.85 and the company has a market cap of $734 M . The 52-week low of the share price is at $316.25.
Company has been under the radar of several Street Analysts.Atrion Corporation is Initiated by BWS Financial to Sell and the brokerage firm has set the Price Target at $300. The Rating was issued on Apr 25, 2016.
Atrion Corporation (Atrion) develops and manufactures products primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. The Company’s fluid delivery products include valves that promote infection control and needle safety. The Company has developed a variety of luer syringe check valves and one-way valves designed to fill hold and release controlled amounts of fluids or gasses on demand for use in various intubation catheter and other applications. The Company also makes tubing clamps in a variety of materials and colors that are compatible with various grades of tubing and sterilization processes and produce specialized intravenous sets for use in numerous applications including anesthesia and oncology. The Company’s principal cardiovascular product is the Myocardial Protection System (MPS2) a technology that delivers essential fluids and medications to the heart during open-heart surgery.